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Abstract
Background: While numerous studies have characterized primary ovarian tumors, little
information is available regarding expression patterns of metastatic sites of this cancer. To define
sets of genes that distinguish primary and metastatic ovarian tumors, we used cDNA microarrays
to characterize global gene expression patterns in 38 effusions (28 peritoneal, 10 pleural) and 8
corresponding primary ovarian tumors, and searched for associations between expression patterns
and clinical parameters.
Results: We observed multidimensional variation in expression patterns among the cancers.
Coordinate variation in expression of genes from two chromosomal regions, 8q and 19q, was seen
in subsets of the cancers indicating possible amplifications in these regions. A set of 112 unique
genes of known function was differentially expressed between primary tumors and effusions using
supervised analysis. Relatively few differences were seen between effusions isolated from the
pleural and peritoneal cavities or between effusions from patients diagnosed with stage III and stage
IV cancers. A set of 84 unique genes was identified that distinguished high from lower grade ovarian
cancers. The results were corroborated using immunocytochemistry, mRNA in situ hybridization,
and immunoblotting.
Conclusion: The extensive variation in expression patterns observed underscores the molecular
heterogeneity of ovarian cancer, but suggests a similar molecular profile for ovarian carcinoma cells
in serosal cavities.
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Epithelial ovarian carcinoma claims more lives than any
other gynecologic malignancy, largely because it fre-
quently escapes detection after it has metastasized [1].
Ovarian carcinoma initially metastasizes primarily to the
serosal surface of the peritoneal cavity and abdominal
organs. The pleural space is often involved as well, either
at diagnosis or, more commonly, at later stages of clinical
progression. Pleural effusion is the most common presen-
tation of stage IV disease [2]. A number of metastasis-asso-
ciated molecules have been reported to be differentially
expressed between primary ovarian tumors and tumor
cells in effusions [3-12], but little is known regarding the
mechanism of metastases.
Molecular characterization of ovarian carcinoma using
DNA microarrays has so far focused on primary tumors
[13-22]. The paucity of data regarding the biological char-
acteristics of ovarian carcinoma cells in effusions at both
the phenotypic and genotypic level limits our understand-
ing of tumor progression in this disease. Specifically, we
do not know how ovarian carcinoma cells in ascites and
pleural effusions differ from those in the corresponding
solid primary tumors, or whether and how carcinoma
cells in peritoneal and pleural effusions differ. Moreover,
molecular analysis of malignant effusions might contrib-
ute to better predictions of survival and treatment
response.
To identify genes whose expression may be associated
with this metastatic behavior, we analyzed global gene
expression patterns of ovarian cancer cells obtained from
3 distinctive anatomic sites: 28 peritoneal, 10 pleural and
8 primary tumors (see supplementary Table S1.xls). A val-
uable feature of this dataset is that it includes 8 paired
samples of primary tumors and malignant effusions from
the same patients. We were able to define a number of
genes that differentiate primary tumors from effusions.
Results
Overview of global gene expression patterns among 
ovarian cancers
We profiled 46 ovarian tumor samples, 38 effusions and
8 primary ovarian carcinomas (Figure 1A–C) using cDNA
arrays representing approximately 26,965 genes and
selected those genes that passed a simple data quality and
variation filter (see Materials and Methods). Using hierar-
chical clustering of the 2863 genes that passed our filter-
ing criteria, we found considerable heterogeneity in the
expression patterns among the tumor samples. The clus-
tering analyses divided the ovarian cancer specimens into
two major groups, with 4 of the 8 primary tumors cluster-
ing together but apart from their paired effusions. It is
noteworthy that the other 4 primaries clustered together
with the effusions from the same patient (Figure 1B). The
major distinguishing feature between the two branches of
the dendrogram was high expression of a number of
chemokines, collagens, cell surface antigens, adhesion
molecules and leukocyte antigens (Figure 1A, panels g, h).
Some of the cancers were notable for the elevated expres-
sion of a cluster of genes residing on chromosome seg-
ment 8q21-24 and the coordinate variation in expression
of these genes suggests that there may be an amplification
of this region of chromosome 8 in some of the ovarian
cancers (Figures 1C, panel b highlighted in red. See also
Figure 4C, panel a). The cancers with chromosome 8q21-
24 overexpression were mostly the paired primary tumors
and effusions.
Genes involved in cell cycle progression and cell prolifer-
ation were variably expressed among the cancers presum-
ably reflecting variation in proliferation rates among the
tumors in a coordinated manner (Figure 1C, panel c)
[23,24]. Co-expression of previously identified markers
for ovarian cancer including kallikreins 6 and 10 as well as
the S100 calcium-binding proteins S100A1 and S100A13
(Figure 1C, panel d) was also seen. Co-clustering of
CEACAM5 and CEACAM7 with syndecan-1 (Figure 1C,
panel e) was observed. These genes were part of a larger
cluster with expression of Keratins 5, 6B, 7, 15 and 19, and
S100A10, caveolin-2 and SLPI (Figure 1C, panel e). In
another cluster (Figure 1C, panel f) the sprouty homologs:
1, 2, and 4, were co-expressed with the dual specificity
phosphatase 6 (DUSP 6) and two ets variant genes 4 and
5 (ETV4 and ETV5), indicating possible involvement of
the MAP kinase pathway in some tumors. Also, co-expres-
sion of caveolin 1 and EGFR was seen, in agreement with
data from experimental models [25,26] (Figure 1C, panel
a). The complete gene list and clustered file is found in
supplementary Figure S1 CDT.cdt.
In order to examine the concordance between expression
at the mRNA level and protein expression, we carried out
immunocytochemistry of CD44, ITGB3, and CD168
(Syndecan-1) on selected samples and show representa-
tive stains (Figure 2, panels A-C). Comparing the ICC
results with the expression result gave good correlation.
Of the 13 samples having both expression data and ICC
for CD44, the 4 with positive ICC had a log2 ratio of
expression from 1 to 2, and the 9 ICC negative had log2
ratio from 0 to -2. For the ITGB3 11 samples had both ICC
and expression data, and of the 3 ICC positive the log2
ratios were from 1 to 2. Of the 8 ICC negatives 7 had
expression ratios from 0 to -2 and one did not correspond
with the expression level with a log2 ratio 1.5. For the Syn-
decan 1 (CD 168) of the 9 ICC positive samples 4 had
log2 ratios from 1.5 to 2, 4 had log2 ratios of 0 and 1 had
a log2 value of -0.5. The 3 ICC negatives had expression
ratios from -1 to -2.Page 2 of 14
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Molecular Cancer 2005, 4:26 http://www.molecular-cancer.com/content/4/1/26In addition, localization to the tumor cells was confirmed.
In situ hybridization was carried out for the ets variant
ETV4 (PEA3) (23 cases) as well as MMP-9 (19 cases) and
MMP-14 (13 cases), demonstrating high mRNA expres-
sion in the tumor cells (Figure 3). These molecules were
chosen since they have been shown to be involved in the
metastatic process and are expressed in ovarian carcino-
mas and to be of prognostic value. Negative and positive
controls for ICC and ISH showed consistent results
through all experiments.
Expression differences between primary tumors, 
peritoneal effusions and pleural effusions
To capture any differences in expression profiles between
primary tumors versus all effusions, SAM analysis was per-
formed on 2863 genes that passed the described filter
Overview of Primary Tumors and EffusionsFigure 1
Overview of Primary Tumors and Effusions. (A) Global gene expression patterns of 46 ovarian cancers: 8 primary tumors, 10 
pleural effusions and 28 peritoneal effusions, were sorted based on similarity of expression following hierarchical clustering. 
2863 genes were selected from the total data set based on variance greater than 2.5 fold in at least 3 arrays. (B) The dendro-
gram is color-coded pink (pleural effusions), blue (peritoneal effusions) and black (primary tumors) to indicate site of origin of 
the cancers. Indicates the clear cell sample. (C) Magnified view of specific gene clusters selected from the entire set of 2863 
genes: (a) Caveolin 1 and EGFR, (b) Chromosome 8 (Genes on Chromosome 8 are denoted in red), (c) Cell Cycle Associated 
Genes, (d) Kallikreins 6, 10, (e) Epithelial, (f) Sprouty cluster, (g) Stromal cluster, (h) immune response cluster. The scale is indi-
cated in the bottom right-hand corner and spans 0.25 to 4 fold over mean (-2 to +2 in log2 space). Missing data are denoted in 
gray.
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Molecular Cancer 2005, 4:26 http://www.molecular-cancer.com/content/4/1/26Immunocytochemistry (ICC) of selected proteinsFigure 2
Immunocytochemistry (ICC) of selected proteins. ICC of (A) CD44, (B) CD61, and (C) Syndecan-1 (CD168) was carried out 
as detailed in 'Materials and Methods'. Expression Data is shown in the top panel and corresponding cases with protein staining 
are denoted with arrows. In panel A the following samples are shown: OV 06A and OV 34P. In panel B the following samples 
are shown: OV 02A, OV12A and OV14A. In panel C the following samples are shown: OV 02A, OV18A and OV20A.
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Molecular Cancer 2005, 4:26 http://www.molecular-cancer.com/content/4/1/26criteria (see Materials and Methods). By this analysis a set
of 112 unique genes of known function that were differ-
entially expressed in these two groups was identified.
(False discovery rate 2%). A partial list of the unique genes
is shown in Table 1 and the complete list may be found in
supplementary Table S2.xls. The relative levels of expres-
sion of several epithelial markers, including claudin 7 and
keratins 7 and 19 were higher in the effusions. The expres-
sion of some genes characteristically expressed in stromal
cells, including SPARC and collagens 1A1, 5A2, and 6A2
was generally higher in the primary tumors than in the
effusions.
The filtered data for the effusions only were then used to
examine gene expression differences among pleural and
peritoneal effusions. Using SAM only 19 unique genes of
known function were identified that significantly varied
between pleural and peritoneal effusions (Table 2), with a
In situ hybridization of selected genesFigure 3
In situ hybridization of selected genes. mRNA in situ hybridization in ovarian carcinoma effusions. Negative control specimen 
(stained with nuclear fast red) and d(T) control are shown in the first row. Two negative (left, stained red) and two positive 
(right, gray) cases using the PEA3 probe are shown in the second row. Two positive (left, stained gray) and one negative (right, 
red) cases using the MMP-9 probe are shown in the third row. Three positive cases using the MMP14 probe are shown in the 
fourth row.Page 5 of 14
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Molecular Cancer 2005, 4:26 http://www.molecular-cancer.com/content/4/1/26Overview of PAM results following clusteringFigure 4
Overview of PAM results following clustering. PAM was carried out to determine differences between the 3 sites examined in 
this study: Primary tumors (Black), peritoneal effusions (Blue) and pleural effusions (Pink). Three main clusters differentiate the 
groups: (a) a set of genes that divides the cluster in to 2 groups and is more highly expressed in the majority of ascites (genes 
mapping to chromosome 8 are denoted in red), (b) a set of genes more highly expressed among the pleural effusions, but also 
expressed in a subset of the ascites, (c) Large cluster over-expressed among the primary tumors.
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Molecular Cancer 2005, 4:26 http://www.molecular-cancer.com/content/4/1/26false discovery rate of 13.5%. Pleural effusions had
significantly higher expression of the angiogenic inducer
CYR61, RAB21, glutathione S-transferase A4 (GSTA4),
and several chemokines when compared to peritoneal
effusions. In addition, expression of the iron transporter,
SLC40A1 was generally lower in pleural effusions than in
the ascites samples. Although some differences in expres-
sion were seen between pleural and peritoneal effusions,
the results provide evidence in favor of a more similar
genetic profile for cancer cells at these two anatomic sites
than for effusions versus the primary tumor.
We then applied a supervised statistical method, PAM
[27] to see whether it was possible to find a set of genes
that could classify the primary tumors from peritoneal
and pleural effusions. By comparing the three groups, a set
of genes (615; 436 unique genes) was identified that cor-
rectly classified the primary tumors and most of the peri-
toneal (error rate 10%) and pleural effusions (error rate
20%). Cross-validation was not as successful, suggesting
again that the difference between the 2 groups of effusions
is not as clear as the distinction between all effusions and
the primary tumors, which is in accordance to the results
of the SAM analyses. Some differences were however
detected. Clustering of the 615 genes (Figure 4 and sup-
plementary Tables S3a, S3b.xls) illustrates that the expres-
sion of a number of chemokine ligands, including CCL2,
CCL8 and CCL3L1 was more frequent in pleural effusions
possibly reflecting the larger number of leukocytes in
these specimens (Figure 4C, panel b). Higher expression
of a number of genes on Chromosome 8q24 was observed
among most of the ascites (Figure 4C, panel a highlighted
in red). In addition, the expression of genes whose pro-
teins have previously been shown to be produced by both
ovarian carcinoma and stromal cells [28-30], including
TIMP-2, vimentin and basic fibroblast growth factor sepa-
rated the primary tumors from the effusions, suggesting
that the cancer-stroma crosstalk is associated with differ-
ent biological pathway activation than that observed in
effusions (Figure 4C, panel c and supplementary Table
S2.xls).
Hierarchical clustering of all 38 effusions was carried out
as described previously. Results were very similar to those
obtained when clustering both the primary tumors and
effusions (Web Supplement, Figure S2.pdf) with the same
11 samples residing on the left branch as in Fig. 1 and
with a strong overexpression of the immune response
cluster of genes (Figure 1h). Interestingly, the majority of
the pleural effusions (6/10) clustered to this branch (p =
0.02).
Identification of Expression Profiles Based on 'Intrinsic' 
Genelist
An 'intrinsic' genelist was constructed to further analyze
the data (see Materials and Methods). The main clusters
identified using this genelist highlighted probable regions
of chromosomal changes on chromosomes 8 and 19 in a
Table 1: Selected genes identified by SAM that are differentially 
expressed in primary tumors vs. all effusions. The complete list is 
available in Table S2.
Genes more highly expressed in Effusions
CLDN7 : claudin 7 : Hs.278562
KRT7 : keratin 7 : Hs.23881
CRIP1 : cysteine-rich protein 1 (intestinal) : Hs.423190
L1CAM : L1 cell adhesion molecule MASA: Hs.1757
ADM : adrenomedullin : Hs.394
CRYAB : crystallin, alpha B : Hs.391270
IL18RAP : interleukin 18 receptor accessory protein : Hs.158315
KRT19 : keratin 19 : Hs.182265
Genes more highly expressed in Primary Tumors
COL6A3 : collagen, type VI, alpha 3 : Hs.80988
COL1A2 : collagen, type I, alpha 2 : Hs.179573
MYB : v-myb myeloblastosis viral oncogene homolog (avian) : Hs.1334
BGN : biglycan : Hs.821
IGFBP7 : insulin-like growth factor binding protein 7 : Hs.119206
SPARC : secreted protein, acidic, cysteine-rich (osteonectin) : 
Hs.111779
AEBP1 : AE binding protein 1 : Hs.118397
APOD : apolipoprotein D : Hs.75736
CDH11 : cadherin 11, type 2, OB-cadherin (osteoblast) : Hs.75929
Table 2: Genes identified by SAM that are differentially 
expressed in Pleural vs. Peritoneal Effusions
Positive Significant Genes: Higher in pleural vs. ascites
NR4A1: nuclear receptor subfamily 4, group A, member 1: Hs.1119
CYR61: cysteine-rich, angiogenic inducer, 61: Hs.8867
CXCL2: chemokine (C-X-C motif) ligand 2: Hs.75765
RAB21: member RAS oncogene family: Hs.184627
CTGF: connective tissue growth factor: Hs.75511
CXCL3: chemokine (C-X-C motif) ligand 3: Hs.89690
TCEB3: transcription elongation factor B (SIII): Hs.155202
IGLL1: immunoglobulin lambda-like polypeptide 1: Hs.348935
CTGF: connective tissue growth factor: Hs.75511
IGHG3: immunoglobulin heavy constant gamma 3: Hs.413826
C1QB: complement component 1, q subcomponent beta: Hs.8986
CYR61: cysteine-rich, angiogenic inducer, 61: Hs.8867
C1QG: complement component 1, q subcomponent gamma:Hs.94953
TAGLN: transgelin: Hs.433399
CD163: Hs.74076
GSTA4: glutathione S-transferase A4: Hs.169907
Negative Significant Genes: Lower in pleural vs. ascites
N33: Putative prostate cancer tumor suppressor: Hs.71119 100791
PLEC1: plectin 1, intermediate filament binding protein 500 kDa: 
Hs.79706
SLC40A1: solute carrier family 40, member 1: Hs.5944Page 7 of 14
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Molecular Cancer 2005, 4:26 http://www.molecular-cancer.com/content/4/1/26subset of tumors (Figure 5C, panels a, b). The majority of
genes in each respective cluster mapped to either 8q21-24
or 19q13. In this analysis, all effusion-primary tumor
pairs clustered together as expected. Furthermore, multi-
dimensional variation was notable in groups of kal-
likreins 6 and 10, S100A1, S100A13, EPAC, laminin γ2
(LAMC2), MUC5B, TRIM 29 and claudin 10 (Figure 5C,
panel c). The kallikreins have been shown to be poten-
tially useful prognostic markers in ovarian cancer [31,32]
and laminin γ2 and MUC5B were shown to display high
expression among some of the cancers at the protein level
as well, using Western analyses (Figure 6). Correlation
between the protein expression and mRNA expression
showed that 3 of the 4 effusions positive for MUC5B pro-
tein had positive log2 ratios. All the cases lacking protein
expression had negative log2 ratios. For the laminin γ2
chain, the protein expression level did not correspond
that well with the mRNA expression although all the pro-
tein-negatives had negative log2 ratios and the majority of
the strongly positive effusion had positive mRNA
expression.
The relationship between FIGO stage and gene expression
patterns was examined using the genes identified in the
intrinsic list. Using SAM, we identified only 7 named
genes and one undefined clone (False Positives, 2.9) that
were more highly expressed in effusions from late stage
(Stage IV) ovarian cancer. Among these genes were PEN2
(presenilin enhancer 2) and PDCD5 (programmed cell
death 5) both residing on 19 q12-13, (Web Supplement,
Table S4.xls). Since most of the stage IV cases in this study
were defined as such by the presence of pleural effusion,
this further underscores the few differences between cells
in effusions in Stage IIIc and Stage IV disease. We identi-
fied 84 genes that distinguished low from high grade dis-
ease (False Discovery Rate of 12.9%, Table 3, Web
'Intrinsic' cluster: Overview of hierarchical clustering with the 'Intrinsic' genelist Overview of 2121 genes selected and magni-fied view of p cific clust rsFigur  5
'Intrinsic' cluster: Overview of hierarchical clustering with the 'Intrinsic' genelist Overview of 2121 genes selected and magni-
fied view of specific clusters. (a) Chromosome 8 associated cluster, (b) Chromosome 19 associated cluster, (c) Variation in 
expression of kallikreins and other genes among the cancers.
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OV12A
OV27B
OV27A
OV08A
OV11A
OV01A
OV25A
OV35P
OV07A
OV31P
OV02A
OV32P
OV37P
ECGP 19q13.11
PEN-2 19q13.11
RPS16 19q13.1
M9 19q13.13
ECH1 19q13.1
MGC20576 19q13.13
MRPS12 19q13.1-13.2
LTBP4 19q13.1-13.2
SUPT5H 19q13
PSMD8 19q13.13
ZNF302 19q13.11
ZNF146 19q13.1
PDCD5 19q12-13.1
UBA2 19q12
___
___
___
___
_________
___
___
___
___
___
___
___Page 8 of 14
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of a family of proteins that may be useful at selectively dis-
tinguishing cancer cells from normal cells that do not
express this antigen. These genes may be important in
understanding the progression of ovarian cancer.
Discussion
We examined global gene expression patterns in primary
ovarian cancers and malignant effusions and found
differences that may be related to tumor progression. Our
results are consistent with many reports that document
the heterogeneity of gene expression patterns noted in
ovarian cancer [14,16-18,20-22]. These data underscore
the heterogeneity of this disease and the profound molec-
ular differences within tumor sub-groups with compara-
ble morphology.
Several clusters of variably expressed genes may have rele-
vance to the biology of ovarian cancer. A large cluster of
genes from chromosome 8q21-24 was more highly
expressed among a subset of the cancers, suggesting an
amplification of this region on chromosome 8. This was
seen in both the primary and the effusions from the corre-
sponding samples with these abnormalities. Transcripts
over-expressed in this cluster include YWHAZ, that
encodes the zeta isoform of 14-3-3 protein (tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activa-
tion protein) family. 14-3-3 proteins are expressed in a
number of cancers and are involved in the cell cycle and
also in prolonging cell survival. TPD52 (hD52) that has
been shown to be in the peak of the 8q21 amplicon in
breast cancer cell lines was also over-expressed in a
number of cancers in this cluster. A recent report suggests
that TPD52 is a candidate target gene and putative onco-
gene at 8q21 [33]. In addition, co-clustering of a number
Western blotting of selected proteinsFigure 6
Western blotting of selected proteins. Immunoblotting of 18 effusions using antibodies directed against Mucin B5 and the lam-
inin γ-chain (Santa Cruz). Mucin B5 (upper panel) is expressed in the specimens in lanes 1,2,3,5,12 and 14. The laminin γ-chain 
is expressed in all specimens except those in lanes 5 and 13. The specimens analyzed were from1 to 17: OV08A, OV09A, 
OV10A, OV12A, OV11A, OV02A, OV04A, OV29P, OV06A, OV01A, OV32P, OV14A, OV12A2, OV18A, OV20A, Additional 
specimen not on array, OV37P.
Table 3: representative list is shown below and the complete list 
is available in Table S5.
DERP6: S-phase 2 protein: Hs.417029
VARS2L: valyl-tRNA synthetase 2-like: Hs.102910
SC5DL: sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, 
fungal)-like: Hs.287749
MYLIP: myosin regulatory light chain interacting protein: Hs.443793
HMGN3: high mobility group nucleosomal binding domain 3: 
Hs.77558
MAGEA6: melanoma antigen, family A, 6: Hs.441113
ATP5L2: ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit g, isoform 2
GPR48: G protein-coupled receptor 48: Hs.160271
MASK: multiple ankyrin repeats, single KH-domain (MASK) homolog: 
Hs.528646
PRO1853: hypothetical protein PRO1853: Hs.433466
YKT6: SNARE protein Ykt6: Hs.296244
ZNF-kaiso: kaiso: Hs.143604
NCK1: NCK adaptor protein 1: Hs.54589Page 9 of 14
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resulting from the intrinsic genelist (Figure 5C, panel a).
Involvement of the MAP kinase pathway may be indicated
in a large number of the cancers in our study based on the
co-expression of the 3 sprouty transcripts (1, 2, and 4)
(Figure 1C panel f). Expression of all three sprouty
homologs has been observed before in mouse develop-
ment [34], but not in human cancers. Human sprouty 2
has been shown to inhibit the mitogen-activated protein
(MAP) kinase pathway [35], and sprouty proteins have
been implicated in the negative regulation of the receptor
tyrosine kinase-induced MAP kinase pathway. DUSP,
another gene in our sprouty cluster, belongs to a family of
9 cytoplasmic and/or nuclear enzymes, that function by
dephosphorylating threonine and tyrosine residues of
p38, JNK and ERK [36,37]. The transcriptional regulation
of Ets transcription factors, including that of PEA3 (ETV4),
on the other hand, involves signals initiated by growth
factor signaling through tyrosine kinase receptors that
may be mediated by MAPK [38]. We have previously
shown that PEA3 and DUSP member PAC-1 predict poor
outcome in ovarian carcinoma, whereas expression of all
three MAPK predicts improved survival [39-41]. The
coordinated expression of 3 sprouty family members,
DUSP6, and ETV4 and 5 in a subset of ovarian cancers
therefore raises the possibility that the activity of a spe-
cific, MAPK-related signaling pathway may have a role in
ovarian cancer.
We have previously shown that clinical and molecular
markers that are of established prognostic role in primary
ovarian cancer have little or no significance in effusions
[42]. Besides the obvious fact that cells at this site repre-
sent tumor progression, they also appear to be biologi-
cally different than tumor cells in both primary tumors
and solid metastases. Using PAM to analyze the three
different groups, primary tumors, and pleural and perito-
neal effusions, we identified a subset of genes that is more
highly expressed in the primary tumors, but fewer differ-
ences between pleural and peritoneal effusions. These
genes are mainly characteristic of previously defined 'stro-
mal' signature [43], but that are produced by both tumor
and stromal cells including collagens, TIMP2, bFGF,
vimentin and SPARC [28-30]. To study tumor progression
we evaluated the expression levels in relation to clinical
parameters using SAM, focusing on FIGO stage and grade.
The most notable distinctions were based on grade rather
than stage.
A large cluster of genes on chromosome segment 19q13.1
showed covarying expression among the cancers in this
study, consistent with previous reports that the 19q13.1
region is amplified in some ovarian carcinomas [44,45].
The AKT2 oncogene contained in this region of
chromosome 19, has been shown to be associated with
the progression of ovarian cancer [44,45]. Interestingly,
we found that some of the genes in the 'chromosome 19
cluster' including PDCD5 and PEN2, were more highly
expressed in the Stage IV cancers than earlier-stage
supporting the notion that amplification of the 19q13.1
region and concomitant elevated expression of these
genes may play a role in the progression of the disease
[46]. Furthermore in a larger cohort of advanced ovarian
carcinomas amplification of this region was found to be
associated with poor survival (Wang et. al., manuscript to
be submitted).
In summary, we have examined the relationship between
primary tumors in ovarian cancer and their corresponding
effusions. The most notable difference was observed in
expression patterns between effusions and the primary
tumors. There is significant molecular variation among
the cancers. There are some hints of differences related to
tumor grade and effusion versus primary tumor that will
need further investigation to see whether these are
significant. Finally, some consistent features of expression
patterns in subsets of the cancers may suggest possible
molecular alterations involved in the biology of the
tumors.
Materials and methods
Effusion specimens
Material consisted of 38 fresh non-fixed peritoneal and
pleural effusions submitted from the Department of
Gynecological Oncology to the Division of Cytology,
Department of Pathology, The Norwegian Radium Hospi-
tal, during the period of April 1998-May 2002. Specimens
were obtained pre-operatively, intra-operatively, or at dis-
ease recurrence, from 36 patients diagnosed with ovarian
carcinoma (35 of the serous type, one clear cell type) and
one patient diagnosed with primary peritoneal carcinoma
(PPC). From one patient, two ascites specimens were
obtained one month apart. Effusion specimens consisted
of 28 peritoneal and 10 pleural effusions. Patient age
ranged from 35 to 73 years (mean = 58 years). Twenty
patients were diagnosed with FIGO stage III disease and
16 with stage IV disease. The remaining patient had a stage
I tumor. Tumor grade for 36 serous carcinomas was as fol-
lows: 5 grade 1, 10 grade 2 and 21 grade 3 carcinomas. All
relevant clinical data were obtained from the Department
of Gynecologic Oncology, and are presented in detail in
web supplementary Table S1.xls. In order to preserve
physiological activity, specimens submitted to our labora-
tory arrived within minutes after collection and were proc-
essed immediately. Cells were suspended and frozen in
RPMI+DMSO at -70°C. Smears and cellblock sections
from all specimens underwent morphological evaluation
by three experienced cytopathologists, and were further
characterized using immunocytochemistry with broadPage 10 of 14
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epitopes, as previously detailed [5,6,47]. In all specimens
included in this study, cancer cells comprised 50% or
more of the entire cell population based on cytology
smears. All patients in this study were treated with plati-
num based chemotherapy according to current guide-
lines, and the samples were collected under an IRB
approved protocol (S-01127; June 22, 2001).
Solid tumors
We obtained samples of primary tumors from 8 of the
patients whose effusions were analyzed. These were snap-
frozen in liquid nitrogen upon removal and stored at -
70°C. Frozen sections were obtained from all biopsies in
order to evaluate the percentage of tumor cells and tissue
viability. The former exceeded 50% of cells in all cases.
RNA isolation, Labeling and Hybridization
Total RNA was isolated from effusions and solid tumors
using the TRIZOL Reagent (Gibco BRL, Life Technolo-
gies). mRNA isolation from total RNA was undertaken
using d(T) coated Dynabeads (Dynal, Oslo, Norway).
One to two µg of experimental sample mRNA was used
for labeling with Cy5-dUTP. mRNA was reverse tran-
scribed with Superscript II (Invitrogen Life Technologies)
using an oligo dT primer (Operon Technologies,
Alameda, CA). Each sample was comparatively hybrid-
ized to cDNA microarrays together with a common refer-
ence labeled with Cy3-dUTP (Stratagene). Fluorescent
dyes were purchased from Amersham Pharmacia Biotech,
Piscataway, NJ. Hybridizations were carried out using the
standard protocol described previously. [23,24]. Com-
plete experimental details may be found at: http://brown
lab.stanford.edu/protocols.html.
DNA Microarrays: All arrays were printed at the Stanford
Functional Genomics Facility. DNA clones on the
microarrays are based primarily the sequence verified
IMAGE clones from the Research Genetics Corporation
(Huntsville, AL) http://www.invitrogen.com/content/sfs/
manuals/sequenceverifiedclones_man.pdf and the CGAP
clone set http://cgap.nci.nih.gov/Genes/PurchaseRea
gents as well as a small percentage of custom spots and
control spots. Complete details regarding the clones on
the arrays may be found at http://www.microarray.org/
sfgf/jsp/servicesFrame.jsp#productionArrays. These
microarrays were comprised of 41,805 elements (42 K),
representing an estimated 25,695 genes as judged by the
number of unique Unigene symbols.
Data Analysis and Clustering
Data Selection: Data were analyzed by using either the
GenePix 3.0 or GenePix 4.0 software (Axon Instruments).
Spots with aberrant measurements due to obvious array
artifacts or poor technical quality were manually flagged
and removed from further analysis. A filter was applied to
omit measurements where fluorescent signal from the
DNA spot was less than 50% above the measured back-
ground fluorescence surrounding the printed DNA spot in
both the Cy3 and Cy5 Channels. Genes that did not meet
these criteria for at least 80% of the measurements across
the cases were excluded from further analysis. Data were
retrieved as log2(Cy5/Cy3). The (Cy5/Cy3) ratio is
defined in Stanford Microarray Database (SMD) as the
normalized ratio of the background-corrected intensities
[48]. Genes whose expression level differed by more than
2.5-fold from their mean expression level in the sample
set in at least 3 samples, were selected for further analysis.
Significance Analysis of Microarrays (SAM)
SAM is a statistical approach to identify genes whose
expression patterns are significantly associated with spe-
cific characteristics of sample sets [49] SAM analysis was
applied to the ovarian dataset to examine differences
between primary, pleural and peritoneal effusions, and to
examine different clinical parameters, including stage and
grade. A two-way, unpaired test was carried out compar-
ing the two groups of interest. A 10-nearest neighbor
imputation engine was applied to estimate missing data
[50], and 500 permutations were carried out to compute
expected values and to calibrate false positive calls.
Prediction Analysis for Microarrays (PAM)
Prediction Analysis for Microarrays (PAM) http://www-
stat.stanford.edu/~tibs/PAM/ was carried out using the
Excel version of the program. This method is applied to
gene expression data to provide sample classification by
'shrunken centroids'. Data were filtered as described ear-
lier for clustering analyses. The three groups used for anal-
ysis were defined as primary tumors, peritoneal effusions
(ascites) and pleural effusions [27].
Intrinsic Genelist
An 'intrinsic' genelist, comprising genes whose expression
varied significantly more between samples from different
patients than between replicate samples for the same
patient, was selected based on the 8 primary tumor/effu-
sion pairs and the paired effusion cancers using methods
as described previously [23]. A score was constructed
which was the average within-pair variation relative to the
between-pair variation. This was the ratio of the variance
of the differences, relative to the variance of the averages.
Immunocytochemical analysis (ICC)
ICC was performed using antibodies directed against Syn-
decan-1 (CD138; SDC1), the integrin β3 subunit (platelet
glycoprotein IIIa, antigen CD61), and CD44 antigen, all
part of identified gene clusters showing variable degrees of
expression among the samples. Negative controls con-
sisted of sections that underwent a similar staining proce-Page 11 of 14
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or that were stained with mouse myeloma protein of the
same isotype as the primary antibody used. Biopsies in
which immunoreactivity for the studied antigens had pre-
viously been demonstrated were used as positive controls.
Western blotting
Frozen effusion specimens were thawed and washed twice
in phosphate buffered saline (PBS). Samples were subse-
quently lysed in 1% NP-40, 20 mM Tris HCl (pH 7.5), 137
mM NaCl, 10% glycerol, 1 mM Phenylmethylsulfonyl-
fluoride, and 1 mM Sodium Orthovanadate, with 0.02
mg/ml aprotinin, leupeptin and pepstatin and 10 µg/ml
phosphatase inhibitor cocktail I. All inhibitors were from
Sigma-Aldrich (Saint Louis, MO). After centrifugation, the
supernatant was collected and protein content was evalu-
ated by the Bradford assay. Twenty-five µg total protein
lysate/lane was resolved by SDS polyacrylamide gel elec-
trophoresis (7.5 or 12 % gels) and transferred on to PVDF
immobilon membranes (Millipore, Bedford, MA). Suc-
cessful transfer was evaluated by staining of membranes
withNaphtol-blue-black (Sigma-Aldrich). Filters were
blocked in TBST containing 5 % dried skimmed milk and
0.05% Tween-20 for 1 hr at room temperature. Thereafter,
the filters were incubated over night at 4°C with primary
antibodies diluted in TBST containing 5 % skimmed milk
and 0.05% Tween-20. Primary antibodies directed against
the laminin γ-2 chain (Santa Cruz Biotechnology, Santa
Cruz, CA) and Muc 5B (Santa Cruz) were chosen as exam-
ples since they were part of novel clusters displaying vari-
ation in expression among the cancers. Filters were
washed 3 times 10 minutes each with TBST (0.05%
Tween-20). They were subsequently incubated with HRP-
conjugated secondary antibody diluted 1:5000 in TBST
containing 5% dried skimmed milk and 0.05% Tween-20
for 45 minutes at room temperature. Immunoreactivity
was detected using the ECL-plus western blotting system
(Amersham-Pharmacia)
mRNA In Situ hybridization (ISH)
Three genes were chosen for ISH as representative exam-
ples for the evaluation of mRNA expression levels in the
tumor cells themselves: MMP-14, MMP-9, and PEA3
(ETV4). The following antisense oligonucleotide probes
were obtained from Research Genetics (Huntsville, AL)
[1-28,51,52]:
MMP-9: 5' CCGGTCCACCTCGCTGGCGCTCCGGU 3',
PEA3: 5' TGA ATT ATG AGA AGC TGA GCC G 3', MMP-
14: 5' TCC ATC ACT TGG TTA TTC CTC ACC CGC C 3'.
A poly d(T)20 oligonucleotide (Research Genetics) was
used to verify the integrity and lack of degradation of
mRNA in each sample. The DNA probes were hyperbioti-
nylated. Stock dilution was prepared with a resulting
equal concentration for both probes. The stock dilution
was diluted with probe diluent (Research Genetics)
immediately before use. Specific sense oligonucleotides
were used for the evaluation of non-specific activity for
each probe.
Cellblock sections (4 micron-thick) of formalin-fixed,
paraffin-embedded specimens were mounted on
ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA).
Sectioning was performed in RNase-free water. Hybridiza-
tion using the probes was carried out as previously
described and by using the microprobe manual staining
system (Fisher Scientific)[53]. Known positive controls
were used in each hybridization reaction. These consisted
of 2 ovarian carcinomas for which positive hybridization
was reproducible in a previous study. Controls for endog-
enous alkaline phosphatase for all probes included treat-
ment of the sample in the absence of the probe and use of
chromogen alone.
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